Phase II study of weekly paclitaxel for docetaxel-resistant metastatic breast cancer in Japan

Breast Journal

Volumn 10, Issue 6, 2004, Pages 509-513

  Taguchi, Tetsuya ^a   Aihara, Tomohiko ^b   Takatsuka, Yuichi ^b   Shin, Eisei ^c   Motomura, Kazuyoshi ^d   Inaji, Hideo ^d   Noguchi, Shinzaburo ^a,e  

^a OSAKA UNIVERSITY   (Japan)

^b KANSAI ROSAI HOSPITAL   (Japan)

^c OSAKA NATIONAL HOSPITAL   (Japan)

^d OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^e OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Docetaxel resistant; Metastatic breast cancer; Phase II; Weekly paclitaxel

Indexed keywords

DOCETAXEL; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANAPHYLAXIS; ARTHRALGIA; ARTICLE; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; JAPAN; LIVER DYSFUNCTION; MULTICENTER STUDY; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; TASTE DISORDER; THROMBOCYTOPENIA;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; JAPAN; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; PALLIATIVE CARE; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 8744237235     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1075-122X.2004.21555.x     Document Type: Article

References (17)

1. Gross P, Heriah YB, Croop JM, et al. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 1986;232:728-31.
2. Piccart MJ. Taxotere: second generation taxoid compound. In: ASCO Education Book, 29th Annual Meeting. Orlando, FL: Bostrom Corp., 1993:25-32.
3. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995;13:2643-55.
4. Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 1994;5:495-505.
5. Bissery MC, Guenard D, Gueritte-Voegelein F, et al. Experimental antitumor activity of Taxotere (RP56976, NSC 628503). A Taxol analogue. Cancer Res 1991;51:4845-52.
6. Nicoletti MI, Lucchini V, D'Incalci M, et al. Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografcs. Eur J Cancer 1994;30A:691-96.
7. Hainsworth JD, Greco FA. Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II trial comparing two schedules. Cancer 1994;74:1377-82.
8. Seidman AD, Hochhauser D, Gollub M, et al. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure. A phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996;14:1877-84.
9. Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997;15:187-92.
10. Klaassen U, Wilke H, Strumberg D, et al. Phase I study with a weekly 1-h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 1996;32A:547-49.
11. Perez EA, Vogel CL, Irwin DH, et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001;19:4216-23.
12. Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16:3353-61.
13. Valero V, Jones SE, Von Hoff DD, et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998;16:3362-68.
14. Jordan MA, Wendell K, Gardiner S, et al. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996;58:816-25.
15. Lopes NM, Adams EG, Pitts TW, et al. Cell kill kinetics and cell cycles effects of Taxol on human and hamster ovarian cell line. Cancer Chemother Pharmacol 1993;32:235-42.
16. Adachi I, Watanabe T, Takashima S, et al. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 1996;73:210-16.
17. Taguchi T, Furue H, Niitani H, et al. Phase I clinical trial of RP56976 (docetaxel) a new anticancer drug [in Japanese]. Gan Kagaku Ryoho 1994;21:1997-2005.